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Surveillance of nosocomial infections in 
Europe: which methodologies? 
Prevalence studies in Europe 
D. Pittet. Infection Control P r o p m ,  The University o f  Geneva 
Hospitals, Switzerland 
Patients admitted to the hospital are at risk of developing nosocomial 
infections (NIs). Surveillance of NIs has been widely accepted 
throughout the world as a primary step towards prevention. The gold 
standard is prospective, on-site, continuous, hospital-wide surveil- 
lance; however, incidence surveys require exhaustive resources. Only 
a few hospitals perform ongoing surveillance for NIs, as do hospitals 
in the USA linked with the NNIS system, CDC. Prevalence studies 
are preferred, primarily due to limited resources, and have been 
conducted during the last 25 years in most European countries. 
Repetitive prevalence surveys are commonly used to assess the 
importance of NIs, and priorities for and impact of infection control. 
Prevalence rates of NIs in European hospitals ranged between 3.5 
and 14.8 per 100 admissions. Methodologies varied between studies. 
To compare the results of a prevalence study on NIs with those of 
other studies requires a knowledge and critical understanding of the 
methods applied. Differences in infection rates might be related to 
differences in surveillance methods and/or study populations; 
furthermore, time of the study and time trends must be considered. 
Thus, important parameters for the interpretation of the study 
findings include the selection of patients and adjustment for case-mix 
and time trends, the methods for identification of NIs, and the 
qualification, training and validation of the observer(s). 
Based on presently available information from national prevalence 
studies in Europe, comparison of infection rates between countries 
should be avoided; consecutive prevalence surveys in the same 
country seem, however, acceptable to assess trends and priorities for 
infection control. 
wl Resistance to antibiotics in European lCUs 
H. Hanberger. Department of Infectious Diseases, University Hospital, 
Linkopping, Sweden 
A high prevalence of decreased antibiotic susceptibility among Gram- 
negative bacilli and Staphylococcus aureus has been reported from ICU 
patients in several European countries. The National Nosocomial 
Infections Surveillance System ofthe Centers for Disease Control and 
Prevention monitors secular trends of antibiotic resistance rates of 
nosocomial pathogens in US hospitals. However, no corresponding 
international surveillance system is operational in Europe. We 
conducted a cross-country comparison of the incidence of antibiotic 
resistance among Gram-negative bacilli from patients in ICUs in 118 
hospitals in Belgium, France, Portugal, Spain and Sweden. Con- 
secutive specimens collected on clinical indications from ICU 
patients were cultured and tested. Minimal inhibitory concentrations 
were determined using Etest. Nine thousand one hundred and sixty- 
six Gram-negative strains were initially isolated from 7308 patients 
between June 1994 and June 1995. MIC breakpoints recommended 
by the National Committee for Clinical Laboratory Standards were 
used. The most frequently isolated organisms were Entero- 
bacteriaceae (59%). followed by Pseudomonas aemginosa (24%). The 
main sources were the respiratory tract (42%), urine (26%), blood 
(14%), abdomen (11%) and skin and soft tissues (7%). Decreased 
antibiotic susceptibility across all species and drugs was highest in 
Portuguese ICUs, followed by French, Spanish, Belgian and Swedish 
ICUs. The highest incidence of resistance was seen in all countries 
among I? aerufinosa (up to 37% resistant to ciprofloxacin in Portu- 
guese lCUs and 46% resistant to gentamicin in French ICUs), 
Enterobacter spp., Acinetobacter spp. and Stenotrophomonas rnaltophilia, 
and in Portugal and France among Klebsiella spp. 
The high incidence of reduced antibiotic susceptibility among 
bacteria in ICUs suggests that more effective strategies are needed to 
control the selection and spread of resistant organisms. 
ml Cost-effectiveness of nosocomiai infection 
surveillance methods 
F. Daschner, Uniu. Hospital Freiburg, Environmental Medicine, Freibq, 
Germany 
The costs of various surveillance methods can best be calculated by 
the time required for finding and recording the hospital-acquired 
infections and the costs saved by the positive impact of surveys on 
infection rates. The sensitivity, specificity and the time required for 
data collection of the following surveillance methods will be given: 
laboratory-based ward surveillance, retrospective chart review, pros- 
pective chart review, risk factor analysis, temperature chart review, 
treatment chart review, unit-based staff self-report. 
A simplified surveillance method for nosocomial bloodstream 
infections and a recently tested selective surveillance method for 
device-associated infections in intensive care units will be presented. 
The selective surveillance method required only one-third of the 
time of the surveillance method used in the NNIS ICU surveillance 
protocol. 
Carbapenems in serious infections: 
maximizing the power, minimizing 
resistance 
MYSTIC: targeted surveillance for serious 
infection 
R.G. Masterton. Western General Hospital, Department of Clinical 
Microbiology, Edinbuyh, UK 
Bacterial resistance is increasing worldwide. Carbapenems are 
currently active against most clinically significant organisms, and 
are stable to type 1 (chromosomal) and extended-spectrum beta- 
lactamases. However, resistance to carbapenems, although rare, has 
been described and it is important to monitor this situation con- 
tinuously. The MYSTIC (Meropenem Yearly Susceptibility Test 
Information Collection) survey is an ongoing international sur- 
veillance program designed to assess the in vitro antimicrobial 
activities of meropenem and comparative antibiotics using standard- 
ized NCCLS methodology. On an annual accumulative basis, 
MYSTIC aims to determine patterns of antibiotic resistance within 
defined patient groups, the relationship of resistance to meropenem 
use and the mechanisms of resistance. The results will enable national 
and international comparisons of antibiotic resistance to be made for 
different types of centers. Each year, for at least 3 years, bacterial 
isolates are being obtained from speciallst units (neutropenia, inten- 
sive care, and cystic fibrosis) and from non-specialist centers 
(especially from patients with intra-abdominal and/or lower 
respiratory tract Infections). All centers must be users of meropenem. 
The antibiotic susceptibility (MIC9o values) of isolates for mero- 
penem and comparator antibiotics are determined and the prevalence 
of resistant strains recorded for each antibiotic. In total, nearly 60 
centers will parmipate in the MYSTIC survey worldwide. Interim 
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results from 36 centers suggest that meropenem is retaining its broad 
spectrum of potency, while resistance is developing to comparator 
antibiotics, including quinolones and the newer cephalosporins. In 
general, MICYO values appear to be highest in neutropenia units, and 
resistance mechanisms are country-specific. The full results of 
MYSTIC are awaited with interest. 
wl Optimizing carbapenem effectiveness in the 
intensive care unit 
N. Vetter. Pulnrologisches Zentrum der Stadt Wieri, 2. Interne 
Abteilung, Vienna, Austria 
Management of bacterial infections in the intensive care unit (ICU) 
presents a special challenge to the infectious disease physician. In 
addition to being severely ill, patients are often compromised by 
invasive devices, such as mechanical ventilators and central venous 
catheters, and may have previously failed antibiotic therapy: all major 
risk factors for acquiring a nosocomial infection. In addition, 
bacterial infections within the ICU, such as pneumonia in ventilated 
patients, are frequently associated with resistant organisms. Such 
infections, many of which are caused by Gram-negative organisms, 
can be dificult to treat and lead to prolonged hospitalization and 
higher inortality rates. Empirical therapeutic strategies need to cover 
a wide range of potential causative organisms, including multiresistant 
bacteria. Current treatment options include the newer cephalo- 
sporins, usually administered in combination with other agents, such 
as aminoglycosides or anti-anaerobic antibiotics. Carbapenems offer 
a suitable option for nionotherapy, as they have potent broad- 
spectrum antimicrobial activity and are stable to most extended- 
spectrum beta-lactaniases. A series of prospective clinical trials in the 
ICU setting have compared meropenem with imipenem/cilastatin or 
combination therapy with ceftazidime plus amikacin. These trials 
indicate that when carbapenems are used as first-line empirical 
therapy in difficult-to-treat patients, they can be highly effective. 
Bacterial resistance or superinfection does not appear to be a major 
concern during the first 3 days of therapy, provided that the 
carbapenenis are dosed appropriately. Early use of carbapenenis, 
particularly in late-onset or ventilator-associated pneumonia, is a 
realistic and effective therapy option. 
ml Role of carbapenems as first-line therapy for 
high-risk febrile neutropenia 
W. Kern. Medirinischc Universitiitskliriik wid Poliklinik, Sektion 
Infektiologie nnd Klinische Immunolqqie, Ulm, Germmy 
combinations of a beta-lactam plus an aminoglycoside have tradi- 
tionally been used as standard empirical therapy for fever in neutro- 
penic patients. New drug developments over the past two decades 
have prompted clinical trials of empirical monotherapy in this setting, 
which offers the possibility of reduced toxicity and lower costs than 
combination therapy. Well-designed, prospective studies have shown 
that selected agents such as ceftazidime can be used as monotherapy, 
provided that prompt and adequate modifications are made in 
response to the clinical course and isolated pathogens. The carba- 
penems have also been studied as monotherapy in febrile neutropenia 
and offer potential advantages over mono- or combination therapy 
using cephalosporins. Compared with third-generation cephalo- 
sporins, imipenem and meropenem have an even broader spectrum 
of antibacterial activity. Patients treated with a carbapenem, parti- 
cularly in high-risk settings such as marrow transplantation or acute 
leukemia, are thus less likely to require modifications in therapy. A 
critical review of several large trials of carbapenem nionotherapy, 
which included high-risk febrile ncutropenic patients, indicates that 
niodifications were indeed less frequently required in the carbapenein 
arms. In terms of adverse events, high doses of imipenem/cilastatin 
have been problematic due to a noticeable incidence of nausea and 
the potential for causing seizures. Meropenein, as well as lower doses 
of imipenem/cilastatin, have been reported to be well tolerated. In 
particular, nephrotoxicity, hypokalemia and rashes are very un- 
common with the carbapenems. Thus, carbapenem monotherapy is 
an effective and well-tolerated option for empirical treatment of 
high-risk febrile neutropenia. 
ml Balancing safety with efficacy in difficult-to- 
treat patients 
R. Norrby. llrriversity Hospital of h a d ,  Departmenf (f Infcctiairs 
Diseases, Lnnd, Sweden 
Difficult-to-treat infections often require therapy with broad- 
spectrum antibiotics. This can be achieved using combinations of 
drugs, although this increases the risk of adverse reactions. The 
carbapenems represent one of the few possibilities of using niono- 
therapy in most patients, thereby limiting the antibiotic exposure to 
a single beta-lactani (a class of drugs generally associated with a good 
safety profile). Adverse hypersensitivity reactions reported with 
carbapenems occur with approximately the same frequency as with 
penicillin. Diarrhea is iiot a major problem in carbapeneni-treated 
patients, probably because the drug concentrations achieved in the 
intestines are low and therefore unlikely to affect the fecal flora. 
Imipenem/cilastatin has been associated with a relatively high 
frequency of seizures if given to patients with central nervous system 
(CNS) problems, in higher doses, and if dosing ic not adju5ted for 
renal function and/or body weight. Meropeneiii is well tolerated by 
the CNS, and can be administered at high doses, e.g. to treat patients 
with meningitis. Rapid administration of iiiiipeneiii/cilastatin can 
lead to nausea and vomiting; to avoid this, higher doses should be 
administered by slow intravenous infusion over 3 0 4 0  min. Mero- 
peneni is associated with a low incidence of nausea and vomiting and 
can even be given as a bolus injection over 5 min. Carbapenrnis thus 
provide an effective and generally well-tolerated option for difficult- 
to-treat patients. O n  balance, nieropeneni appears to offer certain 
benefits with regard to its safety and administration profile. 
wl Meningitis in children-a suitable case for 
carbapenem treatment 
J.S. Bradley. University of Cal$rnia, Ckildrcnk Hospital G H r d t l ~  
Centrv, San Diego, CA, USA 
Antibiotic therapy of bacterial meningitlr in children has changed 
during the past decade, largely due to the appearance of antibiotic- 
resistant Strepfococrns pneumoniae worldwide. With increasing peni- 
cillin resistance in vitro, and reports of clinical failure using 
ceftriaxone and cefotaxime, alternative empirical therapy for 
pneuniococcal meningitis is becoming the standard of care. Options 
for alternative therapy include the addition of vancomycin to either 
ceftriaxone or cefotaxime, or the use of meropenem as nionothcrapy. 
For vancomycin, prospectively collected data are lacking on both 
efficacy and safety in pediatric meningitis. In addition, vancomycin 
is known to cause both renal toxicity and ototoxicity. Mcropenem 
demonstrates increased activity in vitro, against penicillin-resistant 
strains, compared to cefotaxime or ceftriaxone. However, further 
confirmatory clinical evidence is required. Meropeneni has been 
extensively investigated for pediatric meningitis in prospective 
clinical trials, demonstrating an efficacy and safety profile coinpaable 
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to that of cefotaxime. In two large-scale pediatric meningitis trials in 
Europe, Latin America, the USA. South Africa and Israel, 375 
microbiologically and clinically evaluable children were treated with 
either meropenem (n=191) or cefotaxime (n=184). Both treatment 
groups were found to be similar in clinical and microbiological 
efficacy. There were also comparable incidences of seizures, as well 
as clinical and laboratory adverse events as reported by investigators, 
in the two treatment groups. Based on these data, meropenem can 
be considered an appropriate option for empirical monotherapy 
against Hoemophilus influenzae, type b, Neisseria meniryitidis, and 
currently isolated strains of Strt.procorcus pneumoniae. 
New insights into the pathogenesis and 
therapy of sepsis 
F l  Bacterial CpG DNA activates immune cells to 
signal infectious danger 
H. Wagner. Techn. Urtiuersitiit, Inst. f: Med. Mikrobiologie, Munich, 
Germany 
In contrast to nucleotide triplets used as genetic code to translate 
amino acid sequences, immune cells sensing danger code CpG 
nucleotides in a particular base sequence context, termed CpG 
motifs. The frequency of these CpG motifs is normal in bacterial 
DNA, but suppressed In vertebrate DNA. Macrophages and dendritic 
cells, the sentinels bridging innate and adaptive immunity, take up 
bacterial DNA and become activated by CpG motifs to secrete pro- 
inflammatory cytokines, including IL-1, IL-6 and TNF-alpha, to 
upregulate co-stimulatory molecules, including CD40, CD80 and 
CD86, and to produce effector cytokines such as IL-12 and IL-10. 
As such, bacterial CpG DNA causes CD4GCD40 ligand- 
independent maturation of antigen-presenting cells (APCs). Simlar 
to LPS, bacterial CpG DNA can cause, at the extreme, toxic shock 
due to overproduction of TNF-alpha. When used in therapeutic 
concentrations, bacterial CpG DNA promotes Thl-oriented cell- 
mediated immune responses, as shown for leishmania major, Listeria 
monocytogenes and viral infections. Bacterial CpG motifs act as 
adjuvants for CTL and T h l  responses to soluble proteins and 
immunodominant peptides. Used as adjuvant, CpG motifs surpassed 
the gold standard of complete Freunds adjuvant (CFA). 
m] Humoral and cellular factors involved in sepsis 
J. Cohen. Hammenmith Hospital, Infections Diseases, London, UK 
The acute-phase response (APK) is an acute physiologic reaction to 
injuries of various kinds, including infections. It consists of well- 
described quantitative and qualitative changes in the synthesis of a 
variety ofhepatic proteins, and is highly conserved in all endothermic 
species, suggesting that it confers a significant survival advantage. 
Detailed studies of acute-phase serum show that it contains a 
multitude of proteinc, including increased levels of complement, 
coagulation and transport proteins, as well as classic acute-phase 
pentraxin proteins, human C-reactive protein and mouse serum 
amyloid component P (SAP). Leukocyte and endothelial cell 
supernatants were found to be potent stimulators of the APR, and 
the pro-inflammatory cytokines TNF-alpha, IL-1 and IL-6 were 
shown to be the active components in the supernatants responsible 
for initiating the APR. Novel observations from our laboratory have 
revealed that the APR appears to have a role in host defense against 
bacterial infection, and data will be presented demonstrating the 
possible mechanisms by which this occurs. The APR is an enor- 
mously complicated physiologic reaction to injury; nevertheless, if it 
can be manipulated it may be of great clinical benefit. 
wl Sensitization of the host to sepsis and septic 
shock 
T. Calandra. CHUY Lausanne, Switzerland 
Upon stimulation with microbial agents such as the endotoxin of 
Gram-negative bacteria, or the exotoxins or cell wall fragments of 
Gram-positive bacteria, monocytes/macrophages, T-cells, neutrophils 
and endothelial cells release mediators that play a critical role in the 
host response to invasion by these microorganisms. Among the 
cytokines released during the acute phase of infection, WNy and 
macrophage migration inhibitory factor (MIF), one of the first 
cytokines discovered, can sensitize the host and augment the inflam- 
matory response. WNy primes resting monocytes and macrophages, 
upregulating HLA-DK expression and LPS-induced cytokine pro- 
duction. WNy has thus been used to reverse nionocyte deactivation 
in critically ill patents. Preliminary results indicate that WNy therapy 
may ameliorate immune dysfunction in these patients (Nature Med 
1997; 3: 678), yet prospective, randomized, double-blind trials are 
needed to determine the efficacy and safety of such adjunctive 
therapy. Recent observations have ascribed a critical role to MIF in 
the host response to infection. MIF was first rediscovered as a pitui- 
tary peptide released in a hormone-like fashion during endotoxemia 
and the physiologic stress response (Nature 1993; 365: 756). MIF was 
then found to also he a macrophage cytokine secreted after pro- 
inflammatory stimuli (LPS, TSST-1, SPEA, TNF-alpha, IFN- 
gamma) 0 Exp Med 1994;179:1895). Like TNF-alpha and IL-1-beta, 
MIF plays an important role in host response to septic shock. Co- 
injection of rMIF and LPS or E .  coli exacerbates lethality, while 
neutralizing anti-MIF antibodies fully protect mice from lethal shock. 
Once released, MIF also functions to counterbalance the anti- 
inflammatory and immunosuppressive effects of glucocorticoids on 
immune cells (Nature 1995; 377: 68). These data implicate IFN- 
gamma and MIF as important mediators of hosr responses to 
infection, that act in concert with glucocorticoids to regulate 
inflammation and innate immune responses to microbial products. 
1x1 Anti-CD14 monoclonal antibody intervention 
protects from LPS-induced organ injury and 
death in a rabbit model of Gram-negative 
septic shock 
J. Mathison. The Research Institute ofeScripps Clinic, Lajollo, CA, 
USA 
During infection, the innate immune system enables immediate 
recognition and clearance of microorganisms and initiation of the 
adaptive iminune response. Unfortunately, the host response to 
microbial components such as Gram-negative endotoxin also leads to 
organ injury, shock and death. CD14, a macrophage membrane 
protein which is also present as a soluble form in plasma, serves as a 
receptor for LPS, suggesting that blockade of CD14 might limit 
inflammatory injury during Gram-negative infection. We developed 
a monoclonal antibody to rabbit CD14 that blocked LPS binding and 
TNF release in peritoneal niacrophages, and we evaluated the efficacy 
ofthis antibody to block LPS-induced injury in a rabbit model where 
pathophysiologic changes induced by multiple injections of LPS were 
observed over 48 h. Pretreatment with anti-CD14 blocked LPS- 
induced cytokine release, neutropenia, hypotension, organ injury and 
death. Importantly, administration of anti-CD14 after the first 
